

Jonathan Barratt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6732681/publications.pdf>

Version: 2024-02-01

195
papers

11,034
citations

46984

47
h-index

33869

99
g-index

202
all docs

202
docs citations

202
times ranked

6980
citing authors

#	ARTICLE	IF	CITATIONS
1	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. <i>Kidney International</i> , 2009, 76, 534-545.	2.6	1,028
2	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. <i>Kidney International</i> , 2009, 76, 546-556.	2.6	892
3	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	2.6	782
4	Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. <i>Kidney International</i> , 2017, 91, 1014-1021.	2.6	748
5	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.	9.4	505
6	IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2088-2097.	3.0	401
7	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. <i>Kidney International</i> , 2014, 86, 828-836.	2.6	373
8	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	2.6	325
9	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127.	6.3	278
10	Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients. <i>Kidney International</i> , 2001, 60, 969-973.	2.6	269
11	A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 691-701.	3.0	228
12	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
13	The MEST score provides earlier risk prediction in IgA nephropathy. <i>Kidney International</i> , 2016, 89, 167-175.	2.6	190
14	Urine proteomics: the present and future of measuring urinary protein components in disease. <i>Cmaj</i> , 2007, 177, 361-368.	0.9	183
15	The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. <i>Kidney International</i> , 2010, 77, 921-927.	2.6	181
16	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	5.8	160
17	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. <i>Nature</i> , 2020, 583, 90-95.	13.7	148
18	An update on the pathogenesis and treatment of IgA nephropathy. <i>Kidney International</i> , 2012, 81, 833-843.	2.6	136

#	ARTICLE	IF	CITATIONS
19	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135
20	Treatment of IgA nephropathy. <i>Kidney International</i> , 2006, 69, 1934-1938.	2.6	133
21	Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 469-481.	2.2	128
22	Analysis of IgA1 O-Glycans in IgA Nephropathy by Fluorophore-Assisted Carbohydrate Electrophoresis. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1763-1771.	3.0	117
23	Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1889-1904.	3.0	112
24	Pathogenesis of IgA nephropathy. <i>Seminars in Nephrology</i> , 2004, 24, 197-217.	0.6	110
25	O-Glycosylation of Serum IgA1 Antibodies against Mucosal and Systemic Antigens in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3520-3528.	3.0	104
26	Secondary IgA Nephropathy. <i>Seminars in Nephrology</i> , 2008, 28, 27-37.	0.6	99
27	New insights into the pathogenesis of IgA nephropathy. <i>Pediatric Nephrology</i> , 2018, 33, 763-777.	0.9	97
28	From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL. <i>Npj Systems Biology and Applications</i> , 2019, 5, 40.	1.4	96
29	Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2158-2166.	3.0	93
30	Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 2032-2041.	0.4	84
31	Progressive Resistance Exercise Training in CKD: A Feasibility Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 249-257.	2.1	83
32	O-Glycosylation of Serum IgD in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1192-1199.	3.0	77
33	Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1616-1628.	0.4	76
34	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. <i>Pediatric Nephrology</i> , 2017, 32, 139-150.	0.9	71
35	Exaggerated systemic antibody response to mucosal <i>Helicobacter pylori</i> infection in IgA nephropathy. <i>American Journal of Kidney Diseases</i> , 1999, 33, 1049-1057.	2.1	69
36	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1002-1009.	0.4	66

#	ARTICLE	IF	CITATIONS
37	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	2.2	66
38	Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients. <i>Journal of Immunology</i> , 2012, 189, 3751-3758.	0.4	65
39	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
40	Immunopathogenesis of IgAN. <i>Seminars in Immunopathology</i> , 2007, 29, 427-443.	2.8	64
41	Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease. <i>Kidney International</i> , 2019, 96, 429-435.	2.6	63
42	Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. <i>Kidney International</i> , 2017, 91, 235-243.	2.6	62
43	Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy. <i>Seminars in Nephrology</i> , 2018, 38, 461-476.	0.6	61
44	Artificial intelligence and machine learning in nephropathology. <i>Kidney International</i> , 2020, 98, 65-75.	2.6	57
45	The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy (Review) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i>	0.7	56
46	Is immunoglobulin A nephropathy different in different ethnic populations?. <i>Nephrology</i> , 2019, 24, 885-895.	0.7	55
47	New strategies and perspectives on managing IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 577-588.	0.7	55
48	Identification of a novel Fcγ receptor expressed by human mesangial cells. <i>Kidney International</i> , 2000, 57, 1936-1948.	2.6	50
49	β1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells. <i>Kidney International</i> , 2017, 92, 1458-1468.	2.6	49
50	Outcome of Acute Renal Failure Following Surgical Repair of Ruptured Abdominal Aortic Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , 2000, 20, 163-168.	0.8	48
51	Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). <i>Advances in Therapy</i> , 2021, 38, 5361-5380.	1.3	48
52	Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3620-3623.	0.4	47
53	Primary IgA Nephropathy: New Insights Into Pathogenesis. <i>Seminars in Nephrology</i> , 2011, 31, 349-360.	0.6	44
54	T-cell homing receptor expression in IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2540-2548.	0.4	42

#	ARTICLE	IF	CITATIONS
55	B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. <i>Kidney International</i> , 2008, 73, 1128-1136.	2.6	41
56	Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. <i>Advances in Therapy</i> , 2021, 38, 5345-5360.	1.3	39
57	Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 209-218.	2.2	38
58	Why Target the Gut to Treat IgA Nephropathy?. <i>Kidney International Reports</i> , 2020, 5, 1620-1624.	0.4	37
59	Low α -defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction. <i>Science Translational Medicine</i> , 2016, 8, 345ra88.	5.8	35
60	Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression. <i>Kidney International</i> , 2021, 99, 1127-1139.	2.6	35
61	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. <i>Kidney International</i> , 2020, 98, 1009-1019.	2.6	35
62	Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular Outcomes. <i>American Journal of Nephrology</i> , 2015, 42, 285-294.	1.4	33
63	SGLT-2 inhibition in IgA nephropathy: the new standard of care?. <i>Kidney International</i> , 2021, 100, 24-26.	2.6	33
64	The Effect of Resistance Exercise on Inflammatory and Myogenic Markers in Patients with Chronic Kidney Disease. <i>Frontiers in Physiology</i> , 2017, 8, 541.	1.3	32
65	Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria. <i>Kidney International Reports</i> , 2022, 7, 1831-1841.	0.4	32
66	An Update on the Current State of Management and Clinical Trials for IgA Nephropathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2493.	1.0	31
67	Inhibitors Directed towards Caspase-1 and -3 Are Less Effective than Pan Caspase Inhibition in Preventing Renal Proximal Tubular Cell Apoptosis. <i>Nephron Experimental Nephrology</i> , 2004, 96, e39-e51.	2.4	27
68	The Genetics of IgA Nephropathy: An Overview from Western Countries. <i>Kidney Diseases (Basel)</i> , 2021, 10, 27.	1.2	27
69	Is IgA nephropathy the same disease in different parts of the world?. <i>Seminars in Immunopathology</i> , 2021, 43, 707-715.	2.8	27
70	Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial). <i>Kidney International Reports</i> , 2019, 4, 1633-1637.	0.4	26
71	Immune complex formation in IgA nephropathy: CD89 a α -saint α ™ or a α -sinner α ™?. <i>Kidney International</i> , 2010, 78, 1211-1213.	2.6	25
72	Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. <i>Kidney International</i> , 2022, 102, 160-172.	2.6	25

#	ARTICLE	IF	CITATIONS
73	Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management. <i>Frontiers in Immunology</i> , 2020, 11, 572754.	2.2	24
74	Association between native T1 mapping of the kidney and renal fibrosis in patients with IgA nephropathy. <i>BMC Nephrology</i> , 2019, 20, 256.	0.8	23
75	Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy. <i>PLoS ONE</i> , 2016, 11, e0166830.	1.1	23
76	The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease. <i>Biochemical Journal</i> , 2015, 471, 167-185.	1.7	22
77	Multimethods study comparing the experiences of medical clinical academics with nurses, midwives and allied health professionals pursuing a clinical academic career. <i>BMJ Open</i> , 2021, 11, e043270.	0.8	22
78	Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link. <i>International Journal of Immunogenetics</i> , 2022, 49, 8-21.	0.8	21
79	MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 29-37.	1.4	20
80	Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	2.6	20
81	Emerging therapies in immunoglobulin A nephropathy. <i>Nephrology</i> , 2015, 20, 788-800.	0.7	19
82	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. <i>Kidney International Reports</i> , 2022, 7, 993-1003.	0.4	18
83	Treatment of IgA Nephropathy: Evolution Over Half a Century. <i>Seminars in Nephrology</i> , 2018, 38, 531-540.	0.6	17
84	IgA nephropathy: "State of the art" a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description. <i>Kidney International</i> , 2019, 95, 750-756.	2.6	17
85	Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis. <i>Nephron</i> , 2020, 144, 453-458.	0.9	17
86	Inherited IgA glycosylation pattern in IgA nephropathy and HSP nephritis: where do we go next?. <i>Kidney International</i> , 2011, 80, 8-10.	2.6	16
87	Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1078-1085.	0.6	15
88	IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank. <i>Kidney International Reports</i> , 2020, 5, 1643-1650.	0.4	15
89	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2022, 79, 570-581.	2.1	15
90	Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated with IgA-positive B-cells in affected kidneys. <i>Journal of Autoimmunity</i> , 2019, 105, 102309.	3.0	14

#	ARTICLE	IF	CITATIONS
91	What to do with patients with abnormal dipstick urinalysis. <i>Medicine</i> , 2007, 35, 365-367.	0.2	13
92	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. <i>Kidney International</i> , 2021, 100, 1101-1111.	2.6	13
93	International IgA Nephropathy Network Clinico-Pathological Classification of IgA Nephropathy. , 2007, 157, 13-18.		12
94	Reduced proximal tubular expression of protein endocytic receptors in proteinuria is associated with urinary receptor shedding. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 934-943.	0.4	12
95	Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial. <i>Peritoneal Dialysis International</i> , 2019, 39, 486-489.	1.1	12
96	A Pilot Study to Predict Risk of IgA Nephropathy Progression Based on miR-204 Expression. <i>Kidney International Reports</i> , 2021, 6, 2179-2188.	0.4	12
97	MicroRNA-23b-3p Deletion Induces an IgA Nephropathy-like Disease Associated with Dysregulated Mucosal IgA Synthesis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2561-2578.	3.0	12
98	Gluten and IgA nephropathy: you are what you eat?. <i>Kidney International</i> , 2015, 88, 215-218.	2.6	11
99	MO039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	11
100	Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort. <i>Kidney International Reports</i> , 2021, 6, 414-428.	0.4	11
101	Identifying Information Needs of Patients With IgA Nephropathy Using an Innovative Social Mediaâ€stepped Analytical Approach. <i>Kidney International Reports</i> , 2021, 6, 1317-1325.	0.4	10
102	Sugars and immune complex formation in IgA nephropathy. <i>Nature Reviews Nephrology</i> , 2009, 5, 612-614.	4.1	8
103	FC 040INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	8
104	Contactin-1 Antibodies Link Autoimmune Neuropathies to Nephrotic Syndrome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8
105	Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndrome. <i>Clinical and Experimental Medicine</i> , 2009, 9, 291-296.	1.9	7
106	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	2.6	7
107	Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study. <i>BMC Nephrology</i> , 2022, 23, 178.	0.8	7
108	Is sialylation of IgA the agent provocateur of IgA nephropathy?. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2176-2178.	0.4	6

#	ARTICLE	IF	CITATIONS
109	Biomarkers to Predict Progression in IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1421-1423.	2.2	6
110	Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial. <i>Kidney International</i> , 2020, 98, 836-838.	2.6	6
111	The association of muscle size, strength and exercise capacity with all-cause mortality in non-dialysis-dependent CKD patients. <i>Clinical Physiology and Functional Imaging</i> , 2020, 40, 399-406.	0.5	6
112	The Metalloproteinase ADAMTS5 Is Expressed by Interstitial Inflammatory Cells in IgA Nephropathy and Is Proteolytically Active on the Kidney Matrix. <i>Journal of Immunology</i> , 2020, 205, 2243-2254.	0.4	6
113	Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohort. <i>Wellcome Open Research</i> , 2018, 3, 91.	0.9	6
114	Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 873-875.	3.0	6
115	The Iron Biology Status of Peritoneal Dialysis Patients May be a Risk Factor for Development of Infectious Peritonitis. <i>Peritoneal Dialysis International</i> , 2019, 39, 362-374.	1.1	5
116	Macrophage interactions with collecting duct epithelial cells are capable of driving tubulointerstitial inflammation and fibrosis in immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1865-1877.	0.4	5
117	P0344 NEFECONÂ® (BUDESONIDE) SELECTIVELY REDUCES CIRCULATING LEVELS OF BAFF (BLYS) AND SOLUBLE BCMA AND TACI IN IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	5
118	MO258 SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	5
119	IgA nephropathy: a perspective for 2021. <i>Seminars in Immunopathology</i> , 2021, 43, 625-626.	2.8	5
120	Relationship between immunoglobulin A1 lectin-binding specificities, mesangial C4d deposits and clinical phenotypes in immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 318-325.	0.4	5
121	Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort. <i>Kidney International Reports</i> , 2022, 7, 305-318.	0.4	5
122	Interpretation and management of abnormal dipstick urinalysis. <i>Medicine</i> , 2011, 39, 312-316.	0.2	4
123	Biological variation of cardiac troponins in chronic kidney disease. <i>Annals of Clinical Biochemistry</i> , 2020, 57, 162-169.	0.8	4
124	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. <i>Kidney International</i> , 2021, 99, 519-523.	2.6	4
125	A Core Outcome Set for Trials in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 53-64.	2.2	4
126	Mutant mice provide new insight into the role of (mis-)glycation in IgA nephropathy and other glomerular diseases. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1518-1520.	0.4	3

#	ARTICLE	IF	CITATIONS
127	A spoonful of sugar helps the proteinuria go down?. Nephrology Dialysis Transplantation, 2007, 23, 813-815.	0.4	3
128	Evidence-based classification of glomerular pathology. Kidney International, 2014, 86, 1059.	2.6	3
129	Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis. Case Reports in Nephrology, 2015, 2015, 1-5.	0.2	3
130	MP401DIFFERENTIAL MICRORNA EXPRESSION IN SKELETAL MUSCLE OF HUMAN CKD PATIENTS AND HEALTHY CONTROLS. Nephrology Dialysis Transplantation, 2016, 31, i473-i474.	0.4	3
131	IgA nephropathy: driving innovation with a rare renal disease registry. Journal of Kidney Care, 2017, 2, 205-211.	0.1	3
132	A qualitative study of the perspectives of key stakeholders on the delivery of clinical academic training in the East Midlands. JRSM Open, 2018, 9, 205427041774184.	0.2	3
133	Corticosteroids Should Be Used to Treat Slowly Progressive IgA Nephropathy: CON. Kidney360, 2021, 2, 1081-1083.	0.9	3
134	MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNPO23 IN PRIMARY IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	3
135	New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy. Glomerular Diseases, 2022, 2, 15-29.	0.2	3
136	Is IgA Nephropathy a Single Disease?. , 2016, , 3-17.		3
137	Cystic renal disease presenting in pregnancy: a novel presentation of oral-facial-digital syndrome type 1. CKJ: Clinical Kidney Journal, 2008, 1, 23-25.	1.4	2
138	Immunoglobulin A Nephropathy and Related Disorders. , 2014, , 185-192.		2
139	Should Immunosuppressive Therapy Be Used in Slowly Progressive IgA Nephropathy?. American Journal of Kidney Diseases, 2016, 68, 184-186.	2.1	2
140	Assessing the stability and suitability of haematology parameters for diagnosing and monitoring iron deficiency. International Journal of Laboratory Hematology, 2017, 39, e132-e134.	0.7	2
141	TO013PROTEINURIA REDUCTION IN IGA NEPHROPATHY BY NEFECON, A TARGETED‑RELEASE FORMULATION OF BUDESONIDE - RESULTS FROM THE NEFIGAN TRIAL. Nephrology Dialysis Transplantation, 2017, 32, iii82-iii83.	0.4	2
142	Targeted-release budesonide therapy for IgA nephropathy â€œ Authors' reply. Lancet, The, 2017, 390, 2625-2626.	6.3	2
143	208.â€ƒGALACTOSE DEFICIENT IGA1 (GD-IGA1) IN SKIN AND SERUM FROM PATIENTS WITH SKIN-LIMITED AND SYSTEMIC IGA VASCULITIS. Rheumatology, 2019, 58, .	0.9	2
144	MO001ROXADUSTAT FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS: A PHASE 3, RANDOMISED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	2

#	ARTICLE	IF	CITATIONS
145	MO246ESTIMATING DELAY IN TIME TO ESKD FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY AND FSGS*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	2
146	Anticipating, experiencing and overcoming challenges in clinical academic training. British Journal of Health Care Management, 2021, 27, 1-8.	0.1	2
147	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.4	2
148	Rapidly progressive IgA nephropathy: clinicopathological characteristics and outcomes assessed according to the revised definition of the KDIGO 2021 Guideline. Nephrology Dialysis Transplantation, 2022, 37, 2429-2437.	0.4	2
149	IgA Nephropathy: Introduction. Seminars in Nephrology, 2008, 28, 1-3.	0.6	1
150	Study protocol: responding to the needs of patients with IgA nephropathy, a social media approach. CKJ: Clinical Kidney Journal, 2018, 11, 474-478.	1.4	1
151	Pregnancy in IgA Nephropathy: An Effect on Renal Outcome?. American Journal of Nephrology, 2019, 49, 212-213.	1.4	1
152	The Non-Coding RNA Landscape in IgA Nephropathyâ€™Where Are We in 2021?. Journal of Clinical Medicine, 2021, 10, 2369.	1.0	1
153	Other Non-Immunomodulatory Agents. , 2009, , 349-367.		1
154	Immunoglobulin A nephropathy and IgA vasculitis (HSP). , 2020, , C21.8.1-C21.8.1.P61.		1
155	MO209: Baseline Characteristics of Adults Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan For the Treatment of Immunoglobulin A Nephropathy (PROTECT). Nephrology Dialysis Transplantation, 2022, 37, .	0.4	1
156	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney International Reports, 2022, 7, 2076-2080.	0.4	1
157	The role of IgA in proximal tubular cell activation and tubulointerstitial scarring in IgA nephropathy. Lancet, The, 2014, 383, S34.	6.3	0
158	SP011SERUM IGA1 HINGE REGION O-GLYCOSYLATION IS A HERITABLE TRAIT IN CAUCASIANS. Nephrology Dialysis Transplantation, 2015, 30, iii384-iii384.	0.4	0
159	SP083TGF-Î²ETA 1 RELEASE FROM PTEC IS STIMULATED BY GALACTOSE-DEFICIENT POLYMERIC IGA1. Nephrology Dialysis Transplantation, 2015, 30, iii406-iii406.	0.4	0
160	FP201INTERIM RESULTS FROM AN ONGOING PHASE 2 STUDY EVALUATING THE USE OF A MASP-2 INHIBITOR FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN). Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
161	P0500RESULTS OF A PHASE 1 TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BION-1301 IN HEALTHY VOLUNTEERS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
162	P0228THE NEFIGARD TRIAL: THE EFFECT OF NEFECONÂ® (BUDESONIDE) IN PATIENTS WITH PRIMARY IGA NEPHROPATHY AT RISK OF DEVELOPING END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0

#	ARTICLE	IF	CITATIONS
163	The authors reply. <i>Kidney International</i> , 2020, 97, 214-215.	2.6	0
164	FC 074 POOLED EFFICACY AND CARDIOVASCULAR SAFETY RESULTS OF 3 PLACEBO-CONTROLLED AND 1 DARBEPOETIN ALFA-CONTROLLED STUDIES OF ROXADUSTAT FOR TREATMENT OF ANAEMIA IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
165	MO256 THE TREATMENT EFFECT OF RAS BLOCKADE ON PROTEINURIA IN IGA NEPHROPATHY PATIENTS AS A SURROGATE FOR RENAL EVENTS AND DECLINE IN EGFR: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
166	MO326 CORTICOSTEROIDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REPORTED ADVERSE EVENTS IN RANDOMISED CONTROLLED TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
167	FC 030 CONTACTIN-1 IS A NOVEL ANTIGEN IN IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS AND IN CIDP-ASSOCIATED GLOMERULONEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
168	FC 073 REGIONAL EFFICACY AND SAFETY RESULTS OF ROXADUSTAT COMPARED WITH PLACEBO OR DARBEPOETIN ALFA IN NON-DIALYSIS-DEPENDENT (NDD) CHRONIC KIDNEY DISEASE (CKD) PATIENTS WITH ANAEMIA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
169	MO283 IMPACT OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, ON TETANUS- AND DIPHTHERIA-TOXOID VACCINATION-ELICITED IMMUNE RESPONSES IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
170	MO230A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY). <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
171	MO286 DESIGN OF A PH1, MULTICENTER TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PK/PD OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IGA AND A MULTICENTER, OPEN-LABEL EXTENSION STUDY FOR IGA PATIENTS WHO PARTICIPATED IN A PRIOR TRIAL OF BION-1301. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
172	MO540 CARDIOVASCULAR OUTCOMES ASSOCIATED WITH ACHIEVED HAEMOGLOBIN LEVEL IN POOLED PHASE 3 STUDIES OF ROXADUSTAT IN NON-DIALYSIS-DEPENDENT PATIENTS WITH ANAEMIA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
173	Chapter 18 Pharmacology and drug use in kidney disease. , 2008, , .		0
174	Chapter 2 Fluid and electrolyte disorders. , 2008, , .		0
175	Chapter 1 Assessment of renal disease. , 2008, , .		0
176	Chapter 17 Malignancy of the kidney and urinary tract. , 2008, , .		0
177	Chapter 13 Dialysis. , 2008, , .		0
178	Chapter 15 Inherited renal disease. , 2008, , .		0
179	Chapter 4 The kidney in systemic disease. , 2008, , .		0
180	Chapter 3 Glomerular disease. , 2008, , .		0

#	ARTICLE	IF	CITATIONS
181	Chapter 12 Special problems in chronic kidney disease. , 2008, , .		0
182	Chapter 9 Hypertension. , 2008, , .		0
183	Chapter 6 Chronic interstitial disease. , 2008, , .		0
184	Chapter 5 Tubular disease. , 2008, , .		0
185	Chapter 8 Renal stone disease. , 2008, , .		0
186	Chapter 11 Chronic kidney disease (CKD). , 2008, , .		0
187	Chapter 10 Acute kidney injury (AKI). , 2008, , .		0
188	Chapter 16 Structural and congenital abnormalities. , 2008, , .		0
189	Chapter 7 Urinary tract infection. , 2008, , .		0
190	Chapter 14 Renal transplantation. , 2008, , .		0
191	Immunoglobulin A nephropathy and Henoch-Schœnlein purpura. , 2010, , 3971-3977.		0
192	Immunoglobulin A nephropathy and Henoch-Schœnlein purpura. , 2010, , 3971-3977.		0
193	IgA Nephropathy and Henoch-Schœnlein Purpura. , 2014, , 203-213.		0
194	IgA Nephropathy. , 2014, , 467-475.		0
195	IgA Nephropathy in Adults and Children. , 0, , 170-182.		0